Novel delivery methods using lipid nanoparticles or CRISPR-cas-based gene editing therapy has the potential to improve the precision and scalability of BDNF therapies across neurodegenerative diseases, representing a paradigmatic shift from a neuroprotective molecule to regeneration therapy [160]. Here, BDNF is linked to neurodegenerative disease.